Tempus, a leader in artificial intelligence and precision medicine, announced the addition of a novel MRD assay, xM, to its comprehensive testing solutions. The...
In collaboration with leading cancer centers, research results to be presented from four studies across a breadth of breast tumor types and genomic alterations...
Tempus, a leader in artificial intelligence and precision medicine, announced xF Monitor – a new circulating tumor DNA (ctDNA) assay for research use only,...